Simple jQuery Dropdowns
Please use this identifier to cite or link to this item:
Title: Predictors of clinical progression in HIV-1-infected adults initiating combination antiretroviral therapy with advanced disease in the Asia-Pacific region: Results from the TREAT Asia HIV Observational Database
Authors: H. Byakwaga
K. Petoumenos
J. Ananworanich
F. Zhang
M. A. Boyd
T. Sirisanthana
P. C.K. Li
C. Lee
C. V. Mean
V. Saphonn
S. F.S. Omar
S. Pujari
P. Phanuphak
P. L. Lim
N. Kumarasamy
Y. M.A. Chen
T. P. Merati
S. Sungkanuparph
R. Ditangco
S. Oka
G. Tau
J. Zhou
M. G. Law
S. Emery
University of New South Wales (UNSW) Australia
The HIV Netherlands Australia Thailand Research Collaboration
Beijing Ditan Hospital
Research Institute for Health Sciences
Queen Elizabeth Hospital Hong Kong
Hospital Sungai Buloh
National Center for HIV/AIDS
University of Malaya
Institute of Infectious Diseases
Tan Tock Seng Hospital
YR Gaitonde Centre for AIDS Research and Education
National Yang-Ming University Taiwan
Universitas Udayana
Mahidol University
National Center for Global Health and Medicine
Port Moresby General Hospital
Keywords: Immunology and Microbiology;Medicine
Issue Date: 1-Jul-2013
Citation: Journal of the International Association of Providers of AIDS Care. Vol.12, No.4 (2013), 270-277
Abstract: The majority of HIV-infected patients in developing countries commences combination antiretroviral therapy (cART) with advanced disease. We examined predictors of disease progression in patients initiating cART with CD4 count ≤200 cells/mm3 in the TREAT Asia HIV Observational Database. The main outcome measure was progression to either an AIDS-defining illness or death occurring 6 months after initiation of cART. We used survival analysis methods. A total of 1255 patients contributed 2696 person years of follow-up; 73 were diagnosed with AIDS and 9 died. The rate of progression to the combined end point was 3.0 per 100 person years. The factors significantly associated with a higher risk of disease progression were Indian ethnicity, infection through intravenous drug use, lower CD4 count, and hemoglobin ≤130 g/dL at 6 months. In conclusion, measurements of CD4 count and hemoglobin at month 6 may be useful for early identification of disease progression in resource-limited settings. © The Author(s) 2012.
ISSN: 23259582
Appears in Collections:Scopus 2011-2015

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.